Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Risperidone Implant in Schizophrenia
NCT02658357Phase 2Completed
- Sponsor
- Braeburn Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of risperidone in schizophrenia, schizoaffective disorder, sponsored by Braeburn Pharmaceuticals. Started Oct 2015; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02658357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658357.